Concizumab (lebitso la khoebo, Alhemo), sethibela-mafu sa monoclonal se amohetsoe ke FDA ka la 20 Tšitoe 2024 bakeng sa thibelo ea liketsahalo tsa mali ho bakuli ba nang le hemophilia A e nang le factor VIII inhibitors kapa hemophilia B e nang le factor IX inhibitors. E ne e amohetse tumello ke European Medicines Agency (EMA) matsatsing a 'maloa a fetileng ka la 16 Tšitoe 2024 bakeng sa matšoao a tšoanang.
Bakuli ba bang ba haemophilia ba sebelisang "meriana ea clotting factor" bakeng sa ho alafa boemo ba bona ba ho tsoa mali ba hlahisa masole a 'mele (khahlanong le meriana ea clotting factor). Lithibela-mafu tse entsoeng li thibela ketso ea "meriana ea clotting factor" e etsang hore e se sebetse hantle. Boemo bona hajoale bo phekoloa ka ho susumetsa mamello ea 'mele ea ho itšireletsa mafung ka liente tsa letsatsi le letsatsi tsa lintho tse koalang. Kamohelo ea Concizumab (Alhemo) e fa bakuli ba joalo phekolo e ’ngoe.
Concizumab e tsamaisoa letsatsi le letsatsi e le ente ea subcutaneous.
Kamohelo ea Alhemo e ne e itšetlehile ka tlhahlobo ea polokeho le katleho ea eona tekong ea kliniki ea lichaba tse ngata, e nang le libaka tse ngata, e bulehileng, ea mohato oa 3. Tekong, litefiso tsa mali tsa selemo le selemo (ABR) li fokotsoe ka 86% bakeng sa sehlopha sa kalafo sa Alhemo ha se bapisoa le sehlopha sa no prophylaxis.
Mathata a ho tsoa mali ho haemophilia a bakoa ke ho se lekane ha lintho tse koalang. Haemophilia A e bakoa ke khaello ea clotting factor VIII, ha haemophilia B e bakoa ke maemo a tlase a factor IX. Ho haella ha tšebetso ea 'mele ea XI ho ikarabella bakeng sa haemophilia C. Maemo ana a phekoloa ka ho tšela ntho e lokiselitsoeng e rekisoang kapa sehlahisoa se se nang mabaka e le phetoho e sebetsang ea ntho e sieo.
Octocog alfa (Advate), e leng 'genetically engineered using DNA technology' version of clotting factor VIII, hangata e sebediswa bakeng sa thibelo mmoho le kalafo e hlokahalang ya haemophilia A. Bakeng sa haemophilia B, nonacog alfa (BeneFix), eo ke mofuta o hlophisitsoeng oa "clotting factor IX" e sebelisoang hangata.
Hympavzi (marstacimab-hncq), antibody ea motho ea monoclonal targeting "tissue factor pathway inhibitor" e sa tsoa amoheloa e le moriana o mocha oa ho thibela ho tsoa mali ho batho ba nang le haemophilia A kapa haemophilia B.
***
References:
- FDA e fana ka tumello ea ho thibela kapa ho fokotsa makhetlo a ho tsoa mali ho bakuli ba nang le hemophilia A ka li-inhibitors kapa hemophilia B e nang le li-inhibitors. E ngotsoe ka la 20 Tšitoe 2024. E fumaneha ho https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-drug-prevent-or-reduce-frequency-bleeding-episodes-patients-hemophilia-inhibitors-or
- EMA. Alhemo - Concizumab. E fumaneha https://www.ema.europa.eu/en/medicines/human/EPAR/alhemo 'me https://ec.europa.eu/health/documents/community-register/html/h1881.htm
- NHS. Kalafo ea Hemophilia. E fumaneha ho https://www.nhs.uk/conditions/haemophilia/treatment/
- CDC. Phekolo ea Hemophilia. E fumaneha ho https://www.cdc.gov/hemophilia/treatment/index.html
Sehlooho se amanang
- Hympavzi (marstacimab): Kalafo e Ncha ea Haemophilia. Saense ea Europe. E ngotsoe 12 October 2024. E fumaneha ho http://scientificeuropean.co.uk/medicine/hympavzi-marstacimab-new-treatment-for-hemophilia/
***
, a monoclonal antibody was approved by the FDA on 20 December 2024 for prevention of bleeding episodes in patients with hemophilia A with factor VIII inhibitors or hemophilia B with factor IX inhibitors. It had received approval by the European Medicines Agency (EMA) few days ago on 16 December 2024 for the same indications.){kind=link}